Showing results (341-350 of 387) with videos related to
Sort By:
Pageof 39
Mayo Clinic Proceedings|December 4, 2009
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelinesShaji K Kumar, Joseph R Mikhael, Francis K Buadi, et al.American Journal of Hematology|January 11, 2022
Multicentric Castleman disease: A single center experience of treatment with a focus on autologous stem cell transplantationNadine H Abdallah, Thomas Habermann, Francis K Buadi, et al.Blood|January 7, 2006
Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantationAngela Dispenzieri, Martha Q Lacy, Jerry A Katzmann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphomaMatthew J Maurer, Ivana N M Micallef, James R Cerhan, et al.JCO Oncology Practice|October 14, 2022
High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated CourseDarragh F O'Donoghue, Huong L Truong, Heidi D Finnes, et al.American Journal of Hematology|August 20, 2018
Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemiaJithma P Abeykoon, Saurabh Zanwar, Stephen M Ansell, et al.Blood Cancer Journal|July 12, 2025
Integrated genomics with refined cell-of-origin subtyping distinguishes subtype-specific mechanisms of treatment resistance and relapse in diffuse large B-cell lymphomaJanek S Walker, Kerstin Wenzl, Joseph P Novak, et al.Blood Advances|January 11, 2024
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapyJessica F Burlile, Kelsey M Frechette, William G Breen, et al.Blood Cancer Journal|October 9, 2024
DEK regulates B-cell proliferative capacity and is associated with aggressive disease in low-grade B-cell lymphomasMelissa A Hopper, Abigail R Dropik, Janek S Walker, et al.Pageof 39